Ultragenyx Pharmaceutical【0LIF】銘柄情報

ポートフォリオを強化: リアルタイムのディスカッションと実用的な取引アイデア。

プレミアム

通貨

64.79

買値

0.00

売値

0.00

出来高

854

0.00 日の範囲 0.00

64.79 52 週間の範囲 64.79

時価総額

5.32B

前日終値

64.79

始値

時刻

41.58

(O)

最終取引時間

財務取引量

VWAP

平均取引量 (3 か月)

582

発行済株式数

82,114,000

配当利回り

PER

-5.62

1 株当たり利益 (EPS)

-7.39

歳入

434.25M

純利益

-606.64M

セクター

Pharmaceutical Preparations

業界

Pharmaceutical Preparations

ウェブサイト

www.ultragenyx.com

本社

Wilmington, Delaware, USA

設立

Ultragenyx Pharmaceutical Inc is listed in the Pharmaceutical Preparations sector of the ロンドン証券取引所 with ticker 0LIF. The last closing price for Ultragenyx Pharmaceutical was US$64.79. Over the last year, Ultragenyx Pharmaceutical shares have traded in a share price range of US$ 64.79 to US$ 64.79.

Ultragenyx Pharmaceutical currently has 82,114,000 shares in issue. The market capitalisation of Ultragenyx Pharmaceutical is US$5.32 billion. Ultragenyx Pharmaceutical has a price to earnings ratio (PE ratio) of -5.62.

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH) LONDON, Dec. 20, 2024 (GLOBE...

Ultragenyx presenta Evkeeza® (concentrado de evinacumab para solución para infusión) en España para el tratamiento de la hipercolesterolemia familiar homocigótica (HFho)

Ultragenyx presenta Evkeeza® (concentrado de evinacumab para solución para infusión) en España para el tratamiento de la hipercolesterolemia familiar homocigótica (HFho) Evkeeza es un medicamento...

Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

Ultragenyx Receives Positive Recommendation from NICE in the U.K. for Evkeeza® ▼ (evinacumab) for Adolescents and Adults Aged 12 Years and Older with Homozygous Familial Hypercholesterolemia...

Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH)

Ultragenyx Receives European Commission Decision for Evkeeza® (evinacumab) Expanded Indication in Children Aged 5 Years and Older with Homozygous Familial Hypercholesterolemia (HoFH) For the...

Ultragenyx lancia in Italia Evkeeza® (evinacumab concentrato in soluzione per infusione) per il trattamento dell’ipercolesterolemia familiare omozigote (HoFH)

Ultragenyx lancia in Italia Evkeeza® (evinacumab concentrato in soluzione per infusione) per il trattamento dell’ipercolesterolemia familiare omozigote (HoFH) Evkeeza è un farmaco, primo nel...

Zur Behandlung der homozygoten familiären Hypercholesterinämie (HoFH): Ultragenyx führt Evkeeza® (Evinacumab) in Deutschland ein

Zur Behandlung der homozygoten familiären Hypercholesterinämie (HoFH): Ultragenyx führt Evkeeza® (Evinacumab) in Deutschland ein Evkeeza® ist das erste von der U.S. Food and Drug...

MEDIA ADVISORY: Ultragenyx Announces Mepsevii® (vestronidase alfa) Receives Reimbursement Approval for Treatment of Mucopolysaccharidosis VII in Italy

MEDIA ADVISORY: Ultragenyx Announces Mepsevii® (vestronidase alfa) Receives Reimbursement Approval for Treatment of Mucopolysaccharidosis VII in Italy NOVATO, Calif., Sept. 09, 2021 (GLOBE...

期間 †	始値	高値	安値	平均出来高	VWAP
1	64.79	64.79	64.79	34	64.79	DE
4	64.79	64.79	64.79	249	64.79	DE
12	64.79	64.79	64.79	582	64.79	DE
26	64.79	64.79	64.79	390	64.79	DE
52	64.79	64.79	64.79	326	64.79	DE
156	64.79	64.79	64.79	506	64.79	DE
260	64.79	64.79	64.79	319	64.79	DE

0LIF - Frequently Asked Questions (FAQ)

What is the current Ultragenyx Pharmaceutical share price?

The current share price of Ultragenyx Pharmaceutical is US$ 64.79

How many Ultragenyx Pharmaceutical shares are in issue?

Ultragenyx Pharmaceutical has 82,114,000 shares in issue

What is the market cap of Ultragenyx Pharmaceutical?

The market capitalisation of Ultragenyx Pharmaceutical is USD 5.32B

What is the 1 year trading range for Ultragenyx Pharmaceutical share price?

Ultragenyx Pharmaceutical has traded in the range of US$ 64.79 to US$ 64.79 during the past year

What is the PE ratio of Ultragenyx Pharmaceutical?

The price to earnings ratio of Ultragenyx Pharmaceutical is -5.62

What is the cash to sales ratio of Ultragenyx Pharmaceutical?

The cash to sales ratio of Ultragenyx Pharmaceutical is 7.85

What is the reporting currency for Ultragenyx Pharmaceutical?

Ultragenyx Pharmaceutical reports financial results in USD

What is the latest annual turnover for Ultragenyx Pharmaceutical?

The latest annual turnover of Ultragenyx Pharmaceutical is USD 434.25M

What is the latest annual profit for Ultragenyx Pharmaceutical?

The latest annual profit of Ultragenyx Pharmaceutical is USD -606.64M

What is the registered address of Ultragenyx Pharmaceutical?

The registered address for Ultragenyx Pharmaceutical is CORPORATION TRUST CENTER, 1209 ORANGE ST, WILMINGTON, DELAWARE, 19801

What is the Ultragenyx Pharmaceutical website address?

The website address for Ultragenyx Pharmaceutical is www.ultragenyx.com

Which industry sector does Ultragenyx Pharmaceutical operate in?

Ultragenyx Pharmaceutical operates in the PHARMACEUTICAL PREPARATIONS sector

出来高
値上がり率
値下がり率

銘柄コード	株価	出来高
TCFTheracryf Plc	0.725p (38.10%)	7.56M
NMTNeometals Ltd	3.50p (27.27%)	346.81k
SCHOScholium Group Plc	44.00p (25.71%)	30.65k
FABFusion Antibodies Plc	10.15p (24.54%)	3.34M
PYXPyx Resources Limited	3.49p (22.24%)	8.43k
TM1Technology Minerals Plc	0.125p (-24.24%)	37.21M
QUIZQuiz Plc	0.70p (-18.60%)	3.67M
SYMESupply@me Capital Plc	0.003p (-17.81%)	168.35M
OBDOxford Biodynamics Plc	1.20p (-14.29%)	827.83k
ZENZenith Energy Ltd.	5.25p (-13.93%)	5.39M
TRPTower Resources Plc	0.0395p (5.33%)	539.51M
CPXCap-xx Limited	0.1825p (1.39%)	494M
NTVONativo Resources Plc	0.0019p (0.00%)	320.16M
DGIDg Innovate Plc	0.0225p (-13.46%)	208.21M
ENETEthernity Networks Ltd	0.1125p (2.27%)	207.56M